New $138 million facility at GE HealthCare’s Cork manufacturing site will enable 25 million more patient doses of contrast media per year by the end of 2027i
Demand for CT and X-Ray contrast medi...
Agreement drives continued patient access to four important therapies in Japan and Korea
Strengthens Essential Pharma and Clinigen's combined market presence in the JAPAC region
Egham, UK – 6th Feb...
First results from the phase IIIb RELAX clinical trial reinforce the high and sustained efficacy of single treatment of RelabotulinumtoxinA (RelfydessTM) for moderate to severe frown lines (glabella...
